Access the full text.
Sign up today, get DeepDyve free for 14 days.
O. Keene, A. Garrett (2014)
Subgroups: Time to Go Back to Basic Statistical Principles?Journal of Biopharmaceutical Statistics, 24
Vikram Premkumar, Samuel Pan, S. Lentzsch, D. Bhutani (2020)
Use of daratumumab in high risk multiple myeloma: A meta‐analysisEJHaem, 1
S. Giri, A. Grimshaw, S. Bal, K. Godby, P. Kharel, B. Djulbegovic, M. Dimopoulos, T. Facon, S. Usmani, M. Mateos, L. Costa (2020)
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.JAMA oncology
T. Facon, Shaji Kumar, T. Plesner, R. Orlowski, P. Moreau, N. Bahlis, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O'Dwyer, A. Perrot, C. Venner, K. Weisel, J. Mace, N. Raje, M. Attal, M. Tiab, M. Macro, L. Frenzel, X. Leleu, T. Ahmadi, Christopher Chiu, Jianping Wang, R. Rampelbergh, C. Uhlar, R. Kobos, M. Qi, S. Usmani (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.The New England journal of medicine, 380 22
G. Mohyuddin, Monia Sigle, V. Chandrasekar, Muhammad Aziz, Al-Ola Abdallah, L. Shune, B. Mcclune (2020)
Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysisLeukemia & Lymphoma, 61
J. Wittes (2009)
On looking at subgroups.Circulation, 119 7
Letters Corresponding Author: Srikala S. Sridhar, MD, MSc, Princess Margaret Cancer the results of this meta-analysis will be used to justify rou- Centre, University Health Network, 610 University Ave, 7-625 OPG, Toronto, tine up-front use of daratumumab for newly diagnosed HRMM ON, Canada, M5G 2M9 (srikala.sridhar@uhn.ca). without confirmatory evidence. This will result in additional Published Online: February 11, 2021. doi:10.1001/jamaoncol.2020.8017 costs and toxic effects to patients for an uncertain long-term Conflict of Interest Disclosures: Dr Sridhar reported receiving grants and benefit. As the results of the recent SWOG 1211 study show, personal fees from Merck, Roche, Pfizer, AstraZeneca, Bristol Myers Squibb, one cannot simply assume that the addition of a fourth drug Janssen, and Bayer outside the submitted work. No other disclosures were reported. to a 3-drug regimen in the newly diagnosed, high-risk disease 1. Sridhar SS, Blais N, Tran B, et al. Efficacy and safety of nab-paclitaxel vs setting will benefit patients. Even if it offers a progression- paclitaxel on survival in patients With platinum-refractory metastatic urothelial free survival benefit, one cannot know whether the overall tra- cancer: the Canadian Cancer Trials Group BL.12 randomized clinical trial. JAMA jectory of the disease is changed by introducing it earlier
JAMA Oncology – American Medical Association
Published: Apr 18, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.